搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Gloeobacter violaceus Apolipoprotein N-acyltransferase (lnt), partial CSB-YP759510GCI
CSB-EP759510GCI
CSB-BP759510GCI
CSB-MP759510GCI
CSB-EP759510GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Putative pterin-4-alpha-carbinolamine dehydratase 2 (gsl1645) CSB-YP759511GCI
CSB-EP759511GCI
CSB-BP759511GCI
CSB-MP759511GCI
CSB-EP759511GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Transaldolase (tal) CSB-YP759512GCI
CSB-EP759512GCI
CSB-BP759512GCI
CSB-MP759512GCI
CSB-EP759512GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus NAD (P)H-quinone oxidoreductase subunit M (ndhM) CSB-YP759513GCI
CSB-EP759513GCI
CSB-BP759513GCI
CSB-MP759513GCI
CSB-EP759513GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus N utilization substance protein B homolog (nusB) CSB-YP759514GCI
CSB-EP759514GCI
CSB-BP759514GCI
CSB-MP759514GCI
CSB-EP759514GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus 15,16-dihydrobiliverdin:ferredoxin oxidoreductase (pebA) CSB-YP759515GCI
CSB-EP759515GCI
CSB-BP759515GCI
CSB-MP759515GCI
CSB-EP759515GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Sulfate adenylyltransferase (sat) CSB-YP759516GCI
CSB-EP759516GCI
CSB-BP759516GCI
CSB-MP759516GCI
CSB-EP759516GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Lipoyl synthase 1 (lipA1) CSB-YP759517GCI
CSB-EP759517GCI
CSB-BP759517GCI
CSB-MP759517GCI
CSB-EP759517GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Ribose-phosphate pyrophosphokinase (prs) CSB-YP759518GCI
CSB-EP759518GCI
CSB-BP759518GCI
CSB-MP759518GCI
CSB-EP759518GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Phosphopantetheine adenylyltransferase (coaD) CSB-YP759519GCI
CSB-EP759519GCI
CSB-BP759519GCI
CSB-MP759519GCI
CSB-EP759519GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus 50S ribosomal protein L32 (rpmF) CSB-YP759520GCI
CSB-EP759520GCI
CSB-BP759520GCI
CSB-MP759520GCI
CSB-EP759520GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus NAD (P)H-quinone oxidoreductase subunit K 1 (ndhK1) CSB-YP759521GCI
CSB-EP759521GCI
CSB-BP759521GCI
CSB-MP759521GCI
CSB-EP759521GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Ribosomal RNA small subunit methyltransferase G (rsmG) CSB-YP759522GCI
CSB-EP759522GCI
CSB-BP759522GCI
CSB-MP759522GCI
CSB-EP759522GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Potassium-transporting ATPase A chain (kdpA), partial CSB-YP759523GCI
CSB-EP759523GCI
CSB-BP759523GCI
CSB-MP759523GCI
CSB-EP759523GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Phosphate import ATP-binding protein PstB 2 (pstB2) CSB-YP759524GCI
CSB-EP759524GCI
CSB-BP759524GCI
CSB-MP759524GCI
CSB-EP759524GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus 50S ribosomal protein L25 (rplY) CSB-YP759525GCI
CSB-EP759525GCI
CSB-BP759525GCI
CSB-MP759525GCI
CSB-EP759525GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Methylthioribose-1-phosphate isomerase (mtnA) CSB-YP759526GCI
CSB-EP759526GCI
CSB-BP759526GCI
CSB-MP759526GCI
CSB-EP759526GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus DNA repair protein recO (recO) CSB-YP759527GCI
CSB-EP759527GCI
CSB-BP759527GCI
CSB-MP759527GCI
CSB-EP759527GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Ribose-5-phosphate isomerase A (rpiA) CSB-YP759528GCI
CSB-EP759528GCI
CSB-BP759528GCI
CSB-MP759528GCI
CSB-EP759528GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Chromobacterium violaceum tRNA modification GTPase MnmE (mnmE) CSB-YP759529CKA
CSB-EP759529CKA
CSB-BP759529CKA
CSB-MP759529CKA
CSB-EP759529CKA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問(wèn)題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>